AMBIGUOUS RESULTS

Asieris's HAL-PDT hits 57.5% CIN2 regression vs 30.6% for placebo

The Phase 3 APRICITY trial backing Cevira's China approval showed a topical, non-surgical option nearly doubled histologic regression over placebo in a lesion typically treated by excision.

Asieris Pharmaceuticals disclosed Phase 3 APRICITY trial results for Cevira (hexaminolevulinate photodynamic therapy, HAL-PDT) in cervical high-grade squamous intraepithelial lesions, reporting 57.5% histologic regression versus 30.6% for placebo.

By AppliedXLJuly 17, 2026Trial NCT04484415

Executive Summary

A registrational Phase 3 trial of a topical photodynamic therapy for a cervical precancerous lesion showed substantially higher histologic regression than placebo, with viral clearance also observed against the two highest-risk HPV strains.
Cervical high-grade lesions are treated almost exclusively with excisional surgery today, a path that carries reproductive risk for younger women; a topical alternative that spares cervical tissue addresses a real gap in management options.
The disclosure leans on subgroup and post-hoc framing rather than a clean primary-endpoint readout, and the trial's own registry status went dark for more than two years before this result surfaced.
The therapy has already moved past this readout commercially, having secured approval in China and a regulatory filing under review in Europe, positioning the trial as confirmatory rather than a pending binary decision.
The therapy sits in a sparse competitive field for this lesion type, with only a handful of trials sharing its modality or indication, none of which offer a direct head-to-head comparator.

The disclosure

Asieris Pharmaceuticals presented data from its APRICITY trial at a July 17, 2026 symposium held alongside the International Federation for Cervical Pathology and Colposcopy's world congress in Paris, reporting that HAL-PDT produced histologic regression in 57.5% of patients with cervical intraepithelial neoplasia grade 2 (CIN2), a high-grade precancerous lesion, compared with 30.6% on placebo. The trial also reported clearance of high-risk human papillomavirus types 16 and 18, though it did not disclose specific clearance rates. Wen Di of Renji Hospital, Shanghai Jiao Tong University School of Medicine, said the clinical benefits of HAL-PDT are supported by high-quality evidence. Global

What the trial tested

APRICITY is a randomized, quadruple-masked, placebo-controlled Phase 3 trial that enrolled 402 patients across China, comparing topical HAL-PDT against placebo in biopsy-confirmed HSIL, with response assessed against the trial's registered primary outcome measure of responder proportion at six months after first treatment. The therapy is delivered topically via a cervical device rather than systemically, positioning it as a tissue-sparing alternative to excisional procedures such as LEEP and cold-knife conization, which the disclosure frames as carrying obstetric risks including preterm birth and cervical incompetence. NCT04484415+1

The regulatory picture

HAL-PDT has already been approved in China for CIN2, following the APRICITY results, and the European Medicines Agency accepted a Marketing Authorization Application for Cevira covering cervical precancerous lesions in the first quarter of 2026. That timeline means this trial disclosure functions as supporting evidence for a therapy already cleared in one major market, not a pending approval decision. Global

Operational read

The trial's ClinicalTrials.gov registration lists a primary completion date of December 1, 2023, after two upward revisions from an original September 2021 target, and the record has carried an 'Unknown status' label since August 2024. That gap between primary completion and this disclosure spans more than two and a half years, and the readout's own framing leans on subgroup and post-hoc results rather than a confirmed primary-endpoint result. NCT04484415+1

The competitive field

Photodynamic therapy has limited precedent in cervical lesions specifically: a Phase 2 aminolevulinic-acid trial from Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. in cervical neoplasia is the closest same-modality precedent, while a Phase 2 small-molecule trial from Tigris Pharmaceuticals in the same lesion type is the nearest indication-level comparator. Neither trial offers a disclosed head-to-head comparator to HAL-PDT. The broader competitive set in this lesion type is weighted toward HPV-targeted biologics and vaccines still in Phase 1 or Phase 2, rather than topical ablative therapies, suggesting HAL-PDT's non-surgical, tissue-preserving approach occupies a distinct niche rather than a crowded mechanism class.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.